Suppr超能文献

正常血压和高血压大鼠血液及血浆中缓激肽的降解途径。

Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats.

作者信息

Dendorfer A, Wolfrum S, Wagemann M, Qadri F, Dominiak P

机构信息

Institute of Experimental and Clinical Pharmacology and Toxicology, Medical University of Lübeck, D-23538 Lübeck, Germany.

出版信息

Am J Physiol Heart Circ Physiol. 2001 May;280(5):H2182-8. doi: 10.1152/ajpheart.2001.280.5.H2182.

Abstract

Kinins are vasoactive peptide hormones that can confer protection against the development of hypertension. Because their efficacy is greatly influenced by the rate of enzymatic degradation, the activities of various kininases in plasma and blood of spontaneously hypertensive rats (SHR) were compared with those in normotensive Wistar-Kyoto rats (WKY) to identify pathogenic alterations. Either plasma or whole blood was incubated with bradykinin (10 microM). Bradykinin and kinin metabolites were measured by high-performance liquid chromatography. Kininase activities were determined by cumulative inhibition of angiotensin I-converting enzyme (ACE), carboxypeptidase N (CPN), and aminopeptidase P (APP), using selective inhibitors. Plasma of WKY rats degraded bradykinin at a rate of 13.3 +/- 0.94 micromol x min(-1) x l(-1). The enzymes ACE, APP, and CPN represented 92% of this kininase activity, with relative contributions of 52, 25, and 16%, respectively. Inclusion of blood cells at physiological concentrations did not extend the activities of these plasma kininases further. No differences of kinin degradation were found between WKY and SHR. The identical conditions of kinin degradation in WKY and SHR suggest no pathogenic role of kininases in the SHR model of genetic hypertension.

摘要

激肽是一类血管活性肽激素,可对高血压的发展起到保护作用。由于其功效受酶促降解速率的影响很大,因此比较了自发性高血压大鼠(SHR)血浆和血液中各种激肽酶的活性与正常血压的Wistar-Kyoto大鼠(WKY)的激肽酶活性,以确定致病性改变。将血浆或全血与缓激肽(10 microM)一起孵育。通过高效液相色谱法测定缓激肽和激肽代谢产物。使用选择性抑制剂,通过对血管紧张素I转换酶(ACE)、羧肽酶N(CPN)和氨肽酶P(APP)的累积抑制来确定激肽酶活性。WKY大鼠的血浆以13.3±0.94微摩尔·分钟-1·升-1的速率降解缓激肽。酶ACE、APP和CPN占这种激肽酶活性的92%,相对贡献分别为52%、25%和16%。以生理浓度加入血细胞并未进一步扩展这些血浆激肽酶的活性。在WKY和SHR之间未发现激肽降解的差异。WKY和SHR中激肽降解的相同条件表明激肽酶在遗传性高血压的SHR模型中没有致病性作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验